LXRX - Lexicon Pharmaceuticals files $200M mixed shelf offering

Lexicon Pharmaceuticals (NASDAQ:LXRX) has filed for a $200M mixed shelf offering composed of common stock, preferred stock, debt securities, warrants, rights, and units. The filing does not necessarily indicate that a sale has begun, or will occur in the future. The company's two lead candidates are sotagliflozin, in phase 3 for heart failure and type 1 diabetes, and LX9211 for neuropathic pain in phase 1 Lexicon shares are down 1.7% to $3.50 in after-hours trading. Last month, Lexicon's Q2 2021 earnings beat on EPS and revenue.

For further details see:

Lexicon Pharmaceuticals files $200M mixed shelf offering